BofA raised the firm’s price target on HCA Healthcare (HCA) to $470 from $430 and keeps a Neutral rating on the shares after “yet another beat on margins” in what the firm calls a “strong” quarterly report. The firm applies a higher multiple given the outperformance, but thinks that legislative headwinds limit upside, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $490 from $380 at TD Cowen
- HCA Healthcare price target raised to $494 from $445 at Barclays
- HCA Healthcare price target raised to $525 from $495 at UBS
- HCA Healthcare price target raised to $520 from $470 at Goldman Sachs
- HCA Healthcare price target raised to $425 from $400 at Morgan Stanley